With 3,000 people dying of cancer every day within the EU, more anti-cancer drugs are being tested than ever before. The oncology market is currently valued at $34 billion/year and is expected to top $55 billion in 2009. While big pharma is investing up to 20% of its annual research and development budget on the development of cancer treatments, the cancer treatment market is changing with a growing number of cancer subtypes and therefore newer targeted therapies and more complex clinical trials.
This involves challenges in recruiting patients, operational and design issues with global studies, new pharmacogenomics approaches and questions surrounding biomarkers. Oncology researchers need to rethink their clinical development planning strategies in order to ensure that clinical trials are conducted safely, efficiently and in accordance with safety standards and regulations.

ViBevents’ Clinical Trials in Oncology event being held on 11th and 12th November in Berlin aims to establish solutions to both developmental and organisational issues. Through case study driven presentations from leading pharma manufacturers and a series of interactive roundtable discussions, this event will provide best practice solutions to help you comply with existing and upcoming challenges in the market.